Patel Dhavalkumar Dhirajlal reported tax withholding involving 41,158 shares of Sana Biotechnology, Inc. at $4.11 for −$169k on Aug 27, 2026

Tax withholding
Form 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction.
EVP, Chief Scientific Officer
EVP, Chief Scientific Officer
Filed Aug 27, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$169,159.38Shares × reported price
Shares traded
41,158Common Stock
Price per share
$4.11Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
183,352Direct
Trade date
Aug 27, 2026Tax withholding
Filed
Aug 27, 2026, 4:21 PM ET0-day reporting delay
Accession
0002115339-26-000004Code F · Transaction 108991
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 26, 2026Option exercise125,000$0.00$0Trade 108990
Aug 26, 2026Option exercise125,000$0.00$0Trade 108992
3 transaction rows in this filing. Joint filers share the same rows.

SANA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SANA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago +1.7%
Returns since7d −4.2%30d −28%90d180d1y

Footnotes in full

F1: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechology, Inc. ("Sana") common stock. F2: The award vested as to 25% of the restricted stock units on each of August 26, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of August 26, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.